Inhaled Corticosteroid Recommendations for Respiratory Acidosis in Adults

Understanding Treatment Approach

The American Thoracic Society suggests that systemic corticosteroids are the initial treatment for adults with respiratory acidosis, as they have demonstrated mortality benefits and improved outcomes in ARDS and severe respiratory conditions 1, 2

Systemic corticosteroids are suggested for patients with respiratory acidosis associated with ARDS or severe pneumonia, with benefits including reduced mortality (RR 0.84; 95% CI, 0.73-0.96), decreased duration of mechanical ventilation, and shortened hospital stays 1, 2
The American College of Chest Physicians recommends methylprednisolone 0.5 mg/kg every 12 hours for 5-7 days for severe pneumonia with respiratory acidosis, or alternative hydrocortisone at doses <400 mg daily for 5-7 days 3

Systemic corticosteroids may increase the risk of serious hyperglycemia (RR 1.11; 95% CI, 1.01-1.23) and gastrointestinal bleeding (RR 1.20; 95% CI, 0.43-3.34) 1

Close monitoring for adverse effects is essential, particularly in high-risk populations such as immunocompromised patients, patients with metabolic syndrome, and patients in regions with endemic tuberculosis or parasitic diseases 2

The American Thoracic Society recommends avoiding initiation of corticosteroid treatment >2 weeks after ARDS onset, as it may be harmful 2
Patients with severe influenza pneumonia may have increased mortality with corticosteroids, according to the Infectious Diseases Society of America 3